Tag: data

Radcred’s exclusive 2025 study reveals the safest, fastest-paying crypto casinos reshaping online gambling. See trends, data, and tips. 

Discover the latest 29th edition of the *Guide to Venture Capital & Private Equity Firms*, featuring profiles of 3,000 leading firms worldwide. Updated data includes firm details, partner backgrounds, and current corporate activities. Highlights include a U.S. VC dip, AI investment trends, and fintech shifts.

The European data center colocation market is rapidly expanding, valued at $56.72 billion in 2024 and projected to reach $226.76 billion by 2034 with a CAGR of 13.68%. This growth is driven by rising cloud adoption, the need for scalable IT infrastructure, and stringent data protection laws like GDPR. As businesses transition to hybrid IT models, colocation services offer secure, cost-effective solutions that eliminate the need for costly on-premise infrastructure. The market also benefits from trends in edge computing, sustainability, and green energy adoption. Key markets include Frankfurt, Amsterdam, Paris, and London, with expansion in Southern and Eastern Europe.

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that dosing has commenced at the prestigious Weill Cornell Medicine Multiple Sclerosis Center in New York City, in its ongoing Phase 2 clinical trial evaluating intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). This fifth site complements existing sites at Yale University, Johns Hopkins University, Brigham and Women's Hospital, and the University of Massachusetts.

SINGAPORE, June 13, 2025 (GLOBE NEWSWIRE) -- Multi Ways Holdings Limited (“Multi Ways,” the “Company” or the “Issuer”) (NYSE American: MWG), a leading supplier of a wide range of heavy construction equipment for sales and rental in Singapore and the surrounding region, announced that it has filed its annual report on Form 20-F, including its financial results, for the fiscal year ended December 31, 2024 (the “2024 Annual Report”) with the U.S. Securities and Exchange Commission. The 2024 Annual Report can be accessed under the “Investor Relations” section of the Company’s investor relations website at www.multiwaysholdings.com.

SAN FRANCISCO, CALIFORNIA, June 13, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE^® natural killer (NK) cell engager platform, today announced the appointment of David C. Mun-Gavin to its Board of Directors.

– Rademikibart significantly improved lung function and asthma control in patients with eosinophilic-driven type 2 asthma –